Unisys Research on Trustworthy AI Published in Frontiers in Pharmacology Journal
Rhea-AI Summary
Unisys (UIS) announced the publication of its peer-reviewed research paper, “From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing,” in the journal Frontiers in Pharmacology.
The study examines how neurosymbolic AI, which combines advanced AI methods with human knowledge and reasoning, can improve transparency and explainability of AI recommendations in healthcare and other highly regulated industries. It addresses the barrier that many AI systems produce outputs without clearly explaining how conclusions are reached, limiting trust and adoption.
The paper also introduces the MURP framework (Mechanistic Coherence, Uncertainty, Robustness and Provenance), expanding AI evaluation beyond predictive accuracy to criteria needed for use in regulated environments. Unisys states that this work supports its AI-First strategy and aims to help organizations move from AI experimentation to scalable, real-world adoption.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Peer-reviewed study explores how neurosymbolic AI can improve trust and explainability with emerging technologies in healthcare and other regulated industries
Many AI systems can generate outputs but cannot clearly explain how they arrived at them, making it difficult for organizations to evaluate and trust the results. To address this challenge, the research explores a neurosymbolic AI approach that combines advanced AI techniques with human knowledge and reasoning to provide greater transparency into how conclusions are reached.
The paper also introduces a new framework, called MURP (Mechanistic Coherence, Uncertainty, Robustness and Provenance), which extends the evaluation of AI systems beyond predictive accuracy to include criteria needed for use in highly regulated environments.
"The next phase of AI innovation will be shaped not only by performance, but by credibility," said Salvatore Sinno, vice president of innovation, Enterprise Computing Solutions, Unisys. "Organizations are increasingly exploring AI in complex and regulated settings, making the ability to evaluate, govern and stand behind AI-driven outcomes just as important as the outcomes themselves."
This publication further demonstrates how Unisys is advancing AI research that turns emerging capabilities into practical business value. Together with findings from the recently published Unisys AI & Cloud Insights Report 2026, this work supports the company's AI-First strategy and focuses on moving organizations from experimentation to scalable, real-world adoption.
Read the published research paper in Frontiers in Pharmacology and learn more about AI offerings from Unisys.
About Unisys
Unisys is a global technology solutions company that powers breakthroughs for the world's leading organizations. Our solutions – cloud, AI, digital workplace, applications and enterprise computing – help our clients challenge the status quo and unlock their full potential. To learn how we have been helping clients push what's possible for more than 150 years, visit unisys.com and follow us on LinkedIn.
RELEASE NO.: 0902/10068
Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.
UIS-C
View original content to download multimedia:https://www.prnewswire.com/news-releases/unisys-research-on-trustworthy-ai-published-in-frontiers-in-pharmacology-journal-302867163.html
SOURCE Unisys Corporation
FAQ
What AI research did Unisys (UIS) publish in Frontiers in Pharmacology?
Unisys published a peer-reviewed paper titled “From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing” in Frontiers in Pharmacology. The study focuses on making AI systems more explainable and trustworthy for use in regulated settings.
What is neurosymbolic AI in the new Unisys (UIS) study?
In the Unisys study, neurosymbolic AI is described as an approach that combines advanced AI techniques with human knowledge and reasoning. This combination is used to provide greater transparency into how AI systems reach conclusions, helping organizations better evaluate and trust AI-generated recommendations.
What is the MURP framework introduced by Unisys (UIS) AI research?
The Unisys paper introduces the MURP framework, which stands for Mechanistic Coherence, Uncertainty, Robustness and Provenance. It extends evaluation of AI systems beyond predictive accuracy to include criteria that are needed for deployment in highly regulated environments, such as healthcare.
How does the Unisys (UIS) AI paper address trust in healthcare AI systems?
The research addresses a key barrier to AI adoption in healthcare: lack of clear visibility into how AI generates recommendations. By proposing neurosymbolic AI and the MURP framework, it aims to make AI decision processes more transparent, improving organizations’ ability to validate and trust AI outputs.
How does this publication support the Unisys (UIS) AI-First strategy?
Unisys states that the publication demonstrates progress in AI research that turns emerging capabilities into practical business value. Together with its AI & Cloud Insights Report 2026, the work is presented as supporting the company’s AI-First strategy and helping organizations move from experimentation to scalable adoption.
Which industries does the Unisys (UIS) trustworthy AI research target?
The study focuses on healthcare and other highly regulated industries. It explores how to provide clear visibility into AI recommendations so that organizations in these sectors can better evaluate, govern and stand behind AI-driven outcomes.